Elena Giudice

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “PARP inhibitors, use early in the first-line maintenance therapy setting but with caution”.

PARP inhibitors, use early in the first-line maintenance therapy setting but with caution

Annals of Translational Medicine(2023)10.21037/atm-2022-81

N/A

0DataRank · unranked

2 citations

Yong Man Kim, Jung‐Min Lee, Elena Giudice

The role of innate immune system in modulating CHK1 inhibitor (CHK1i) response in BRCA wild-type (BRCAwt), platinum-resistant high-grade serous ovarian cancer (PR-HGSOC): Exploratory analysis from a phase II study of CHK1i prexasertib.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5557

N/A

0DataRank · unranked

1 citations

Jayakumar R. Nair, Tzu‐Ting Huang, Min-Jung Lee, Jane B. Trepel, Jungmin Lee +1 more

579-D Multiplex imaging of ovarian carcinoma reveals spatial cell interaction patterns predictive of immunotherapy responses

DOAJ (DOAJ: Directory of Open Access Journals)(2023)10.1136/jitc-2023-sitc2023.0579-d

N/A

0DataRank · unranked

0 citations

Jung‐Min Lee, Elena Giudice, Edward C. Schrom, Andrea J. Radtke, Nitasha Gupta +4 more

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

Nature Communications(2024)10.1038/s41467-024-47215-6

N/A

0DataRank · unranked

42 citations

Tzu‐Ting Huang, Jayakumar R. Nair, Grant Zurcher, Ann McCoy, Darryl Nousome +14 more

Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009–2023)

European Journal of Cancer(2025)10.1016/j.ejca.2025.115589

N/A

0DataRank · unranked

6 citations

Charalampos S. Floudas, Marco Filetti, Tommaso Giovagnoli, Stefano Sganga, Antonio Vitale +13 more

Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancer

Research Square(2025)10.21203/rs.3.rs-7724642/v1

N/A

0DataRank · unranked

0 citations

Junya Tabata, Tzu‐Ting Huang, Elena Giudice, Kristen R. Ibanez, Jayakumar R. Nair +13 more